MedTrace Logo

Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma

NCT02296164 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2020-03-04

Study results available
· View outcomes & findings →

Summary

The Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL) who are receiving therapy with Valchlor. Patients will be followed prospectively for a maximum of 2 years from the date of signed informed consent (enrollment) until end of study. Continuation in the study is not contingent on continuation of Valchlor.

Conditions

  • Mycosis Fungoides

Interventions

DRUG

Valchlor

Valchlor gel 0.016%

Sponsors & Collaborators

  • Helsinn Therapeutics (U.S.), Inc

    lead INDUSTRY

Principal Investigators

  • Bill Bailey · Helsinn Therapeutics (U.S.), Inc

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-12
Primary Completion
2018-10-17
Completion
2018-10-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02296164 on ClinicalTrials.gov